{"name":"Shanghai CP Guojian Pharmaceutical Co., Ltd.","slug":"shanghai-cp-guojian-pharmaceutical-co-ltd","ticker":"","exchange":"","domain":"","description":"","hq":"","founded":0,"employees":"","ceo":"","sector":"","stockPrice":0,"stockChange":0,"stockChangePercent":0,"marketCap":"","metrics":{"revenue":0,"revenueGrowth":0,"grossMargin":0,"rdSpend":0,"netIncome":0,"cash":0,"dividendYield":0,"peRatio":0,"fiscalYear":"FY2026"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"}],"diseaseAreas":[{"name":"Oncology","slug":"oncology","revenue":0,"percentOfTotal":0,"drugCount":2,"colorKey":"oncology","drugs":[{"name":"CHOP, CMAB304","genericName":"CHOP, CMAB304","slug":"chop-cmab304","indication":"Cancer (specific indication not publicly detailed)","status":"phase_3"},{"name":"CHOP combined with CMAB304","genericName":"CHOP combined with CMAB304","slug":"chop-combined-with-cmab304","indication":"Lymphoma or hematologic malignancy (specific indication not publicly confirmed)","status":"phase_3"}]}],"pipeline":[{"name":"CHOP, CMAB304","genericName":"CHOP, CMAB304","slug":"chop-cmab304","phase":"phase_3","mechanism":"CMAB304 is a monoclonal antibody that targets and inhibits a specific immune checkpoint or tumor-associated antigen to enhance anti-tumor immunity.","indications":["Cancer (specific indication not publicly detailed)"],"catalyst":""},{"name":"CHOP combined with CMAB304","genericName":"CHOP combined with CMAB304","slug":"chop-combined-with-cmab304","phase":"phase_3","mechanism":"CHOP chemotherapy combined with CMAB304 (a monoclonal antibody) targets cancer cells through cytotoxic chemotherapy while enhancing immune response through antibody-mediated mechanisms.","indications":["Lymphoma or hematologic malignancy (specific indication not publicly confirmed)"],"catalyst":""}],"recentEvents":[],"realNews":[{"url":"https://news.google.com/rss/articles/CBMigAFBVV95cUxNNC1lbGZmZUw1QXpCOUotam52cDloS3RwbnhUWnBlN2JrTUVUMUw5enJEZjVLYmNaeEdid2tYQUgtSEZNSWZpc0Y4QVViSnY4WmNWZ0lKRC1kUzZiRUdGSXJyc3BWTEo1UzRyZERSOXF5YmVNOW81aWZHc1ZxaGd0Sw?oc=5","date":"2026-01-04","type":"patent","source":"Insightace Analytic","summary":"Psoriasis Biosimilars Market Size, Share and New Trends 2026 to 2035 - Insightace Analytic","headline":"Psoriasis Biosimilars Market Size, Share and New Trends 2026 to 2035","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiggFBVV95cUxQYjNrb1ZmNkxHdmlkS1RNZjJ6Q0VtT1d1d1ZMUXN6alNnOUVjM0s1bHFWWURZSFJHckxjWXJ0eU85UG9YVHBXTVBFUkFCQjFHSUFTam5VRWxwLVp2WFlJRzFmdTFnSFZJU0NTbk5idmttXy1faVJRU3lVOUNqWGVXWTJ3?oc=5","date":"2025-06-25","type":"patent","source":"Insightace Analytic","summary":"TNF Biosimilars Market is expected to grow at a 16.5% CAGR during the forecast period for 2025-2034. - Insightace Analytic","headline":"TNF Biosimilars Market is expected to grow at a 16.5% CAGR during the forecast period for 2025-2034.","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMipwFBVV95cUxPekdDSWFSTVRwUGZiZDVDbkFWMFVwZUpNeEctcGlocjZxMXdjY0lIejlwQkdPUkRQZmk2YWVGX012V1JkZUdXcWFMQi1EVHJSem9fd2NtYXJ0bDk0Zm1KUjFobEFoei1MbVBpbEZnWll1eDN3NjVxLXRFZzJES1RfTjM4anJLcWhBSGRieG5fYy1LZFlQbUk4YzdzMUc4Y3MxWElWTE9pOA?oc=5","date":"2021-07-04","type":"patent","source":"Generics and Biosimilars Initiative","summary":"Biosimilars of abatacept - Generics and Biosimilars Initiative","headline":"Biosimilars of abatacept","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMitgFBVV95cUxPejhCQlcwcEc3Y1FXNG15U1ZBaWZUdWdkUWlGUDQ4ZjFYSFg5TTBTVG1xaS1UWjA1Y3VSbTBCTDJQbDJfQTBPaDZ1T0dlTHN3bFZtcXc5Q1owdEd4MGdTb2VzZ0s3cWlBYlR4dlVsTGZGYl9KR0t1WmhmeTVrQWx5UmZzeWMtLUFHOUJVdThkZF9rakpwMWNGMHlvSkl5MEZQTVV5UlF6WUVFdUVGX3NJdEE5d3Nwdw?oc=5","date":"2014-02-19","type":"pipeline","source":"Technology Networks","summary":"IMAPAC to Bring Together Over 150 Leading Industry Players - Technology Networks","headline":"IMAPAC to Bring Together Over 150 Leading Industry Players","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiiAJBVV95cUxNR0pxZWtGektLV3RHYU8zbkpLYnE1emhaTW5oYTg1NjFNbXNFTVlzQ0E1TjVlSjFLQzROV3QtZ285em5XU2NJeVBQYW44QW14SGgweDdmaVdwUTRNVkc4WFVURXpmdGUyQXZTQlJwZXhXME4yS3hMUnVaeGF5SjBCTmtOUjBubGNXRFAtbkpwVjNta3k2dXVuNlpSWGtOVW1hbDdsVmJ1WTlxSUgxdlBaUUliZlFQQzlocGgxbjA0MHRsVWozZmE2cDVQbHdvWFhHcXdJNkxLckRBTFhBVVFiREFndU5IOE1USkEzOGc3OWZfTWhUNjdZaVlSdnp6Y3JINlFTc19GUno?oc=5","date":"2013-04-18","type":"patent","source":"eHealth Magazine","summary":"Cipla launches ETACEPT – the first Biosimilar of Etanercept in India under the brand name ETACEPT for the treatment of Rheumatic Disorders - eHealth Magazine","headline":"Cipla launches ETACEPT – the first Biosimilar of Etanercept in India under the brand name ETACEPT for the treatment of R","sentiment":"neutral"},{"url":"https://news.google.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?oc=5","date":"2013-04-17","type":"patent","source":"Mint","summary":"Cipla launches India's first biosimilar drug - Mint","headline":"Cipla launches India's first biosimilar drug","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMie0FVX3lxTFBfb3d2emU4Zm5NcXRfTTc2ZGstWGVDWDZ0cHRrcHlrV2Npc24zVGo4ZWdra1RLbU5QaFlaTVRaSVVSMkRtcWVtV3NDcUVvb0JTSGR4Ry1IUWFZZTAwTWN2S0xkX1FpQnV4OHFKUmgwNFFEVkdXbnNtTVZvdw?oc=5","date":"2008-05-27","type":"pipeline","source":"Pharmaceutical Technology","summary":"Shanghai CP Guojan API Production Suite, Shanghai - Pharmaceutical Technology","headline":"Shanghai CP Guojan API Production Suite, Shanghai","sentiment":"neutral"}],"patents":[],"drugCount":2,"phaseCounts":{"phase_3":2},"enrichmentLevel":0,"visitCount":3,"keyCompetitors":[],"therapeuticFocus":[],"financials":null,"yahoo":null}